Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Issue : The Pharmaceutical Journal, 10/17 May 2014, Vol 292, No 7809/10

Sort by: Newest first Oldest first A-Z Z-A

  • Multiple sclerosis Subscription

    15 MAY 2014 13:24

    The National Institute for Health and Care Excellence hasopened a consultation on a clinical practice guideline on multiple sclerosis

  • Make asthma SIMPLE for your patients Subscription

    10 MAY 2014 By Anna Murphy
    Comments (1)

    This week saw the publication of the first national study of asthma deaths in the UK. Its findings provide some powerful statements for pharmacy. Anna Murphy explains.

  • Do not dismiss Relvar Ellipta based on theoretical concerns Subscription

    10 MAY 2014 By Stuart Hill

    Although the promotion of medicines safety should be applauded, I disagree with the concerns of Tony Capstick and colleagues (PJ, 22 February 2014, p199) because they do not appear to be evidence based. Although comparative potencies of corticosteroids is an important issue, this lies in the theoretical realm. If randomised controlled trials assessing patient-oriented outcomes have shown the product to fall into the category ...

  • The risks with using sodium valproate Subscription

    10 MAY 2014 By Sid Dajani

    I was impressed with the thought-provoking piece concerning the use of sodium valproate to treat epilepsy in pregnant women and the associated risks (PJ 2014;292:482).

  • Improving the safe use of medicines Subscription

    10 MAY 2014 By Lynn Haygarth

    The need to improve patient safety is now greater than ever with both the Shipman report and the Francis inquiry into care at Mid-Staffordshire NHS Foundation Trust showing that existing services can sometimes let the public down. It is evident that pharmacists should be recognised as the forefront in improving the safe use of medicines and devices as outlined in the “Now or never” report from the Royal Pharmaceutical Society.

  • Demonstrating our value Subscription

    10 MAY 2014 By Martin Astbury, Ash Soni

    Following the publication of the Royal Pharmaceutical Society “Now or never” report and subsequent pharmacy “Call to action” it is crucial pharmacists are utilised as professionals to maximise outcomes and help improve and protect the public’s health.

  • Seeking solutions Subscription

    10 MAY 2014 By David Bearman

    Many of us are worrying about the future. For some time we have focused our efforts on gaining a national voice that can be heard alongside that of the doctors. This is a laudable aim, as is the creation of national templates for services and best practice standards. But, even with the substantial moves forward, we have found ourselves with: An increase in student numbers which could lead to employment issues and blight young pharmacists’ futures Increasing work ...

  • Patient care records can improve our practice Subscription

    10 MAY 2014 By Luca Viani

    We provide advice and counselling to patients on a daily basis but these could be considered unsafe without an accurate patient history. Full patient care records are crucial to our practice.

  • We’re not that different from the US Subscription

    10 MAY 2014 By Graeme Smith

    Gareth Malson writes about a Walgreens pharmacy he visited in California and hopes that we will not see the like here in Britain. I fear that ship has already sailed.

  • Best interests? Subscription

    10 MAY 2014 By Mike Brunt

    The interview of Peter Bainbridge, Boots director of pharmacy (PJ 2014;292:396), leaves me feeling somewhat confused.

Show  10 per page20 per page50 per page

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.